Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

نویسندگان

  • Margot Mutsch
  • Weigong Zhou
  • Philip Rhodes
  • Matthias Bopp
  • Robert T Chen
  • Thomas Linder
  • Christian Spyr
  • Robert Steffen
چکیده

BACKGROUND After the introduction of an inactivated intranasal influenza vaccine that was used only in Switzerland, 46 cases of Bell's palsy were reported. METHODS We conducted a matched case-control study and a case-series analysis. All primary care physicians, ear, nose, and throat specialists, and neurologists in German-speaking regions of Switzerland were requested to identify cases of Bell's palsy diagnosed in adults between October 1, 2000, and April 30, 2001. Each physician was invited to select three control patients for each patient with Bell's palsy, with matching according to age, date of the clinic visit, and physician. Vaccination information was provided by the physicians. RESULTS A total of 773 patients with Bell's palsy were identified. Of the 412 (53.3 percent) who could be evaluated, 250 (60.7 percent) were enrolled and matched with 722 control patients; the other 162 patients had no controls. In the case-control study, we found that 68 patients with Bell's palsy (27.2 percent) and 8 controls (1.1 percent) had received the intranasal vaccine (P<0.001). In contrast to parenteral vaccines, the intranasal vaccine significantly increased the risk of Bell's palsy (adjusted odds ratio, 84.0; 95 percent confidence interval, 20.1 to 351.9). Even according to conservative assumptions, the relative risk of Bell's palsy was estimated to be 19 times the risk in the controls, corresponding to 13 excess cases per 10,000 vaccinees within 1 to 91 days after vaccination. In the case-series analysis, the period of highest risk was 31 to 60 days after vaccination. CONCLUSIONS This study suggests a strong association between the inactivated intranasal influenza vaccine used in Switzerland and Bell's palsy. This vaccine is no longer in clinical use.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Immunogenicity of Concentrated and Purified Inactivated Avian Influenza Vaccine Formulation

Avian influenza (AI) H9N2 is a low pathogenic virus subtype belonging to Orthomyxoviridae family. Given the prevalence of this subtype as an infectious agent in poultry industry, special attention has been always directed toward the development of vaccine production against this infection. The vaccine of this infection is produced by killing the virus and using a mixture of inactivated antigen ...

متن کامل

The efficacy of inactivated oil-emulsion H9N2 avian influenza vaccine

An experimental inactivated oil-emulsion H9N2 avian influenza vaccine was formulated with 3 parts ofinactivated avian influenza antigen A/Chicken/Iran/101/1998(H9N2) emulsified in 7 parts of oil adjuvant.Twelve week-old specific pathogen-free (SPF) chickens were divided into seven groups of 10 birds. Sixgroups were vaccinated with 1, 1/10th, 1/50th, 1/100th, 1/200th and 1/400th field dose of th...

متن کامل

Use of N-trimethyl chitosan for intranasal delivery of DNA encoding M2e-HSP70c in mice

BACKGROUND: Influenza outbreak has become a great lifethreateningdisease in the world. Nasal vaccines can inducesystemic IgG and mucosal IgA antibody responses, whichestablish two layers of immune defense against the infectiouspathogens like influenza. Mucosal vaccines must overcomeseveral limitations, including the mucociliary clearance andinefficient uptake of soluble antigens. Therefore, nas...

متن کامل

Safety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study

We studied the safety of a trivalent inactivated surface antigen (split virion, inactivated) influenza vaccine, Begrivac® (Novartis Company), widely used in health care workers in Kurdistan. A longitudinal follow-up study was performed in Sanandaj city, west of Iran, recruiting 936 people. A questionnaire was completed for each participant, and all symptoms or abnormal physical findings were re...

متن کامل

Partial Quality Control of Inactivated Split Human Influenza Vaccine 2008-9

Background and Aims: Influenza vaccination is one of the best way to prevent and control influenza worldwide. It is manufactured by WHO-licensed companies based on the WHO expertise committee annually. The aim of this study was partial quality control of the commercial human influenza vaccine 2008-9 and its matching with the circulating strains. Materials and Methods: The trivalent imported vac...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The New England journal of medicine

دوره 350 9  شماره 

صفحات  -

تاریخ انتشار 2004